Search Results

Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.

• Authors : Andrikopoulou A; Department of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.; Zografos E

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*drug therapy ; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives

• Source: Clinical breast cancer [Clin Breast Cancer] 2021 Jun; Vol. 21 (3), pp. e212-e219. Date of Electronic Publication: 2020Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium:

Record details

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.

• Authors : Van den Nest M; Department for Evidence-based Medicine and Clinical Epidemiology, Donau-Universität Krems, Dr.-Karl-Dorrek-Straße 30, 3500, Krems, Austria. .; Glechner A

Subjects: Administration, Intravenous* ; Injections, Subcutaneous* ; Treatment Outcome*

• Source: Systematic reviews [Syst Rev] 2019 Dec 11; Vol. 8 (1), pp. 321. Date of Electronic Publication: 2019 Dec 11.Publisher: BioMed Central Country of Publication: England NLM ID: 101580575 Publication Model: Electronic Cited Medium: Internet ISSN: 2046-4053

Record details

Dennis Slamon.

• Authors : Tharp, Mike

Subjects: *BREAST cancer; *TRASTUZUMAB; *ONCOLOGISTSCALIFORNIA; LOS Angeles (Calif.); UNITED StatesUNIVERSITY of California, Los Angeles...

• Source: U.S. News & World Report. 12/28/98-01/04/99, Vol. 125 Issue 25, p63. 2p. 1 Color Photograph.

Record details

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.

• Authors : Lang, Yitian; Wu, Bin; Liu, Xiaoyan

Subjects: HORMONE receptor positive breast cancer; TRASTUZUMAB; BREAST cancerUNITED States

• Source: Breast Cancer: Targets & Therapy; Dec2022, Vol. 14, p453-463, 11p

Record details

A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care.

• Authors : Eriksson, Mikael; Destounis, Stamatia; Czene, Kamila

Subjects: TOMOSYNTHESIS; BREAST; BREAST cancerUNITED States

• Source: Science Translational Medicine; 5/11/2022, Vol. 14 Issue 644, p1-10, 10p

Record details

Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database.

• Authors : Nahleh, Zeina A; Elimimian, Elizabeth B; Elson, Leah C

Subjects: BREAST tumor treatment; ANTINEOPLASTIC agents; CELL receptorsUNITED States

• Source: Breast Cancer: Basic & Clinical Research; 8/4/2020, Vol. 14, p1-12, 12p, 5 Charts, 3 Graphs

Record details

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.

• Authors : Mills, Matthew, N.; Walker, Chelsea; Thawani, Chetna

Record details

Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients.

• Authors : Moustafa, Sherif; Murphy, Katie; Nelluri, Bhargava K.

Subjects: CANCER relapse; HEART ventricle diseases; ANALYSIS of varianceUNITED States

• Source: Echocardiography; Mar2016, Vol. 33 Issue 3, p406-415, 10p

Record details

AFTER 25 YEARS, A BIG PAYOFF.

• Authors : Arnst, Catherine; Yang, Catherine; Elstrom, Peter

Subjects: *BIOTECHNOLOGY; *PHARMACEUTICAL industry; TRASTUZUMABUNITED StatesGENENTECH Inc. GENENTECH Inc. GENENTECH Inc. DNA

• Source: BusinessWeek. 06/01/98, Issue 3580, p147-148. 2p. 1 Color Photograph.

Record details

Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.

• Authors : Bloom, Meghan, J.; Jarrett, Angela, M.; Triplett, Todd, A.

Record details